Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[11] Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study
Carella, Angelo M.
de Souza, Carmino A.
Luminari, Stefano
Marcheselli, Luigi
Chiappella, Annalisa
Di Rocco, Alice
Cesaretti, Marina
Rossi, Andrea
Rigacci, Luigi
Gaidano, Gianluca
Merli, Francesco
Spina, Michele
Stelitano, Caterina
Hohaus, Stefan
Barbui, Anna
Puccini, Benedetta
Miranda, Eliana C.
Guida, Annalisa
Federico, Massimo
LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 53 - 57
[12] Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma
Umino, Kento
Fujiwara, Shin-Ichiro
Ikeda, Takashi
Kawaguchi, Shin-Ichiro
Toda, Yumiko
Ito, Shoko
Ochi, Shin-Ichi
Nagayama, Takashi
Mashima, Kiyomi
Minakata, Daisuke
Nakano, Hirofumi
Yamasaki, Ryoko
Morita, Kaoru
Kawasaki, Yasufumi
Yamamoto, Chihiro
Ashizawa, Masahiro
Hatano, Kaoru
Sato, Kazuya
Oh, Lekuni
Ohmine, Ken
Muroi, Kazuo
Kanda, Yoshinobu
LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1926 - 1933
[13] A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
Arcari, Annalisa
Rigacci, Lugi
Tucci, Alessandra
Puccini, Benedetta
Usai, Sara Veronica
Cavallo, Federica
Fabbri, Alberto
Balzarotti, Monica
Pelliccia, Sabrina
Luminari, Stefano
Pennese, Elsa
Zilioli, Vittorio Ruggero
Mahmoud, Abdurraouf Mokhtar
Musuraca, Gerardo
Marino, Dario
Sartori, Roberto
Botto, Barbara
Gini, Guido
Zanni, Manuela
Hohaus, Stefan
Tarantini, Giuseppe
Flenghi, Leonardo
Tani, Monica
Di Rocco, Alice
Merli, Michele
Vallisa, Daniele
Pagani, Chiara
Nassi, Luca
Dessi, Daniela
Ferrero, Simone
Cencini, Emanuele
Bernuzzi, Patrizia
Mammi, Caterina
Marcheselli, Luigi
Tabanelli, Valentina
Spina, Michele
Merli, Francesco
BLOOD ADVANCES, 2023, 7 (15) : 4160 - 4169
[14] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
Witzig, T. E.
Vose, J. M.
Zinzani, P. L.
Reeder, C. B.
Buckstein, R.
Polikoff, J. A.
Bouabdallah, R.
Haioun, C.
Tilly, H.
Guo, P.
Pietronigro, D.
Ervin-Haynes, A. L.
Czuczman, M. S.
ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
[15] The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
Cencini, Emanuele
Tucci, Alessandra
Puccini, Benedetta
Cavallo, Federica
Luminari, Stefano
Usai, Sara Veronica
Fabbri, Alberto
Pennese, Elsa
Marino, Dario
Zilioli, Vittorio Ruggero
Balzarotti, Monica
Petrucci, Luigi
Tafuri, Agostino
Arcari, Annalisa
Botto, Barbara
Zanni, Manuela
Hohaus, Stefan
Sartori, Roberto
Merli, Michele
Gini, Guido
Al Essa, Wael
Musurca, Gerardo
Tani, Monica
Nassi, Luca
Daffini, Rosa
Mammi, Caterina
Marcheselli, Luigi
Bocchia, Monica
Spina, Michele
Merli, Francesco
HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 78 - 87
[16] Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi
Arcari, Annalisa
Tabanelli, Valentina
Merli, Francesco
Marcheselli, Luigi
Merli, Michele
Balzarotti, Monica
Zilioli, Vittorio Ruggero
Fabbri, Alberto
Cavallo, Federica
Casaluci, Gloria Margiotta
Tucci, Alessandra
Puccini, Benedetta
Pennese, Elsa
Di Rocco, Alice
Zanni, Manuela
Flenghi, Leonardo
Gini, Guido
Sartori, Roberto
Chiappella, Annalisa
Usai, Sara Veronica
Tani, Monica
Marino, Dario
Arcaini, Luca
Vallisa, Daniele
Spina, Michele
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (04) : 653 - 662
[17] Male and Female Fertility: Prevention and Monitoring Hodgkin' Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors. A Systematic Review by the Fondazione Italiana Linfomi
Viviani, Simonetta
Caccavari, Valentina
Gerardi, Chiara
Ramadan, Safaa
Allocati, Eleonora
Minoia, Carla
Guarini, Attilio
Di Russo, Anna
CANCERS, 2021, 13 (12)
[18] Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study
Barnes, Jeffrey A.
Redd, Robert
Fisher, David C.
Hochberg, Ephraim P.
Takvorian, Tak
Neuberg, Donna
Jacobsen, Eric
Abramson, Jeremy S.
HEMATOLOGICAL ONCOLOGY, 2018, 36 (04) : 633 - 637
[19] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
Martin Garcia-Sancho, A.
Baile, M.
Rodriguez, G.
Dlouhy, I.
Sancho, J. M.
Jarque, I.
Gonzalez-Barca, E.
Salar, A.
Espeso, M.
Grande, C.
Bergua, J.
Montes-Moreno, S.
Redondo, A.
Enjuanes, A.
Campo, E.
Lopez-Guillermo, A.
Caballero, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
[20] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
Terui, Yasuhito
Rai, Shinya
Izutsu, Koji
Yamaguchi, Motoko
Takizawa, Jun
Kuroda, Junya
Ishikawa, Takayuki
Kato, Koji
Suehiro, Youko
Fukuhara, Noriko
Ohmine, Ken
Goto, Hideki
Yamamoto, Kazuhito
Kanemura, Nobuhiro
Ueda, Yasunori
Ishizawa, Kenichi
Kumagai, Kyoya
Kawasaki, Atsuko
Saito, Tomohisa
Hashizume, Misato
Shibayama, Hirohiko
CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854

← 1 2 3 4 5 →